<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968109</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-020</org_study_id>
    <secondary_id>2014-002605-38</secondary_id>
    <nct_id>NCT01968109</nct_id>
  </id_info>
  <brief_title>Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors</brief_title>
  <official_title>A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability, characterize the dose-limiting toxicities, and
      identify the maximum tolerated dose of BMS-986016 alone and in combination with Nivolumab in
      subjects with select advanced (metastatic and/or unresectable) solid tumors and to provide
      preliminary information on the clinical benefits of the combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with Adverse Events (AEs)</measure>
    <time_frame>Approximately Up to 4 years</time_frame>
    <description>Grade 3 or higher per CTCAE v4 (Common Terminology Criteria for Adverse Events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with Serious Adverse Events (SAEs)</measure>
    <time_frame>Approximately Up to 4 years</time_frame>
    <description>Grade 3 or higher per CTCAE v4 ( Common Terminology Criteria for Adverse Events)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Deaths</measure>
    <time_frame>Approximately Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with laboratory abnormalities</measure>
    <time_frame>Approximately Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of a dosing interval (Ctau) [Eg: concentration at 336 hours] of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
    <description>AUC = area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation (DF) or fluctuation index ([Cmax - Ctau]/Css,avg]) of BMS-986016 administered both alone and in combination with nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by tumor assessment (RECIST)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 using Best overall response (BOR), Objective response rate (ORR), Duration of response (DOR) and Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity measured by ADA for BMS-986016 (all subjects) and nivolumab</measure>
    <time_frame>Approximately 2.3 years</time_frame>
    <description>Timeframe: Up to 1.8 years + 135 days posttreatment follow-up (total of up to approximately 2.3 years)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval from centrally read electrocardiograms (ECGs)</measure>
    <time_frame>up to 12 eight-week cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Neoplasms by Site</condition>
  <arm_group>
    <arm_group_label>BMS-986016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986016 specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986016 + BMS-936558</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986016 + BMS-936558 specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986016</intervention_name>
    <arm_group_label>BMS-986016</arm_group_label>
    <arm_group_label>BMS-986016 + BMS-936558</arm_group_label>
    <other_name>Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936558</intervention_name>
    <arm_group_label>BMS-986016 + BMS-936558</arm_group_label>
    <other_name>Anti-PD-1 (Anti-Programmed-Death-1)</other_name>
    <other_name>MDX-1106</other_name>
    <other_name>Nivolumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  For Dose escalation: subjects with cervical, ovarian, bladder and CRC, head and neck,
             gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma
             and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing
             while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed
             while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.

          -  For Dose Expansion: all of the above in escalation except for cervical, ovarian
             bladder and CRC

          -  Progressed, or been intolerant to, at least one standard treatment regimen, except
             for subjects in 1st line cohorts.

          -  ECOG performance status of 0 or 1

          -  At least 1 lesion with measurable disease at baseline

          -  Availability of an existing tumor biopsy sample (and consent to allow pre-treatment
             tumor biopsy)

        Exclusion Criteria:

          -  Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as
             the only site of active disease

          -  Autoimmune disease

          -  Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed
             consent

          -  Uncontrolled CNS metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gajewski, Site 0003</last_name>
      <phone>773-702-2085</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Lipson, Site 0004</last_name>
      <phone>410-502-9380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Stephen Hodi, Site 0001</last_name>
      <phone>617-582-7603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Weise, Site 0011</last_name>
      <phone>313-576-8599</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Callahan, Site 0005</last_name>
      <phone>646-888-3359</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Med Ctr</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Sanborn, Site 0002</last_name>
      <phone>503-215-2604</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Upmc Eye And Ear Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Ferris, Site 0010</last_name>
      <phone>412-623-0327</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shailender Bhatia, Site 0008</last_name>
      <phone>206-288-6765</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universtaet Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Hoeller, Site 0024</last_name>
      <phone>+4314040015350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universtaet Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Preusser, Site 0023</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0028</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vlllejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Tumorzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Bauer, Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Curigliano, Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0025</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0015</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Peters, Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitat Zurich</name>
      <address>
        <city>ZB B rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Dummer, Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Forster, Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Larkin, Site 0022</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms by Site</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
